Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
183
resultados
Última actualización
30/05/2025 [06:52:00]
Resumen de: AU2025203403A1
0324 The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
Resumen de: AU2023406303A1
Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA), wherein the LNP comprises an ionizable lipid; a "helper" lipid, e.g., a ceramide or distearoylphosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, as well as uses thereof.
Resumen de: AU2023406273A1
The present application discloses single stranded deoxyribonucleic acid (DNA) molecules comprising at least one nucleic acid sequence of interest flanked by a first at least one stem loop structure, methods of making and method of use for delivery and expression of a transgene in host cells.
Resumen de: AU2023375377A1
The disclosure provides conjugates comprising a targeting moiety, e.g., an antibody, Fab fragment or single chain variable fragment (ScFv), and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload), wherein the targeting moiety, e.g., antibody, Fab fragment or the ScFv, is conjugated to the lipid nanoparticle through a linker, and wherein the linker comprises an enzyme recognition sequence and a Click product formed from a Click reaction between a first Click handle on the targeting moiety, e.g., antibody, Fab fragment, or ScFv, and a second Click handle on the LNP.
Resumen de: AU2023406321A1
The present disclosure provides novel polymer-conjugated lipids, e.g., comprising DODA conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations.
Resumen de: AU2023375378A1
The disclosure provides conjugates comprising a targeting moiety, e.g., an antibody, Fab fragment or single chain variable fragment (ScFv), and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload), wherein the targeting moiety, e.g., antibody, Fab fragment or the ScFv, is conjugated to the lipid nanoparticle through a linker, and wherein the linker comprises an enzyme recognition sequence and a Click product formed from a Click reaction between a first Click handle on the targeting moiety, e.g., antibody, Fab fragment, or ScFv, and a second Click handle on the LNP.
Resumen de: AU2023383821A1
Provided are cationic lipid compounds represented by formula (I), which can be applied to lipid nanoparticles such that the lipid nanoparticles can target different tissue organs for drug delivery. The cationic lipid compounds or a lipid nanoparticle composition comprising same can specifically deliver a preventive/therapeutic agent, especially a nucleic acid component, to a target organ.
Resumen de: AU2023382622A1
Lipid nanoparticles (LNPs) containing particular cationic ionizable lipids with a biologically active polynucleotides (e.g., RNAs) are provided. In some aspects, the LNP complexes are provided as aerosols and/or dry powders, such as for delivery to the lungs. Methods of making and using such compositions are provided.
Resumen de: AU2023406483A1
The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types,
Resumen de: AU2025203258A1
Abstract The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Resumen de: EP4559483A1
A hyaluronic acid derivative pharmaceutical composition includes an active ingredient suspended in an aqueous carrier containing a hyaluronic acid derivative, in which the active ingredient is a fine particle having a molecular weight of 100 g/mol or greater and 8000 g/mol or less. It is preferable that the fine particle is a microparticle or a nanoparticle.
Resumen de: EP4559896A1
The present invention addresses the problem of providing, without using relatively expensive starting materials, a more conveniently synthesizable pH-sensitive cationic lipid and a lipid nanoparticle that contains this pH-sensitive cationic lipid. The present invention is a pH-sensitive cationic lipid represented by general formula (I). R<sup>1</sup> is a C1-22 hydrocarbon group; the three R<sup>1</sup> groups in one molecule may be the same as or different from each other; Z<sup>1</sup> is a C1-6 alkylene group or a single bond; X is -N(R<sup>2</sup>)(R<sup>3</sup>) or is a 5- to 7-membered nonaromatic heterocyclic group (with the proviso that this group is bonded to Z<sup>1</sup> via a carbon atom); and R<sup>2</sup> and R<sup>3</sup> are each independently a hydrogen atom or a C1-4 hydrocarbon group, or R<sup>2</sup> and R<sup>3</sup> may be bonded to each other to form a 5- to 7-membered nonaromatic heterocycle.
Resumen de: EP4559895A1
The present invention provides: a neutral lipid capable of suppressing the phase transition of endosomal membranes caused by phosphatidylcholine from being inhibited; and a lipid nanoparticle containing the neutral lipid. The present invention pertains to an ionic neutral lipid comprising a compound represented by general formula (I). In formula (I), R<sup>1</sup> is a C1-22 hydrocarbon group; three R<sup>1</sup> groups in one molecule may be the same as or different from each other; a1 and a2 are each independently an integer of 0 to 4; b1 and b2 are 0 or 1, satisfying b1+b2=1; R<sup>2</sup> and R<sup>3</sup> are each independently a hydrogen atom or a C1-3 alkyl group; and R4 is an anionic group.
Resumen de: CN119604279A
A method of making hybrid lipid particles suitable for delivery of brittle active ingredients, such as nucleic acids, the method comprising the steps of preparing hybrid lipid particles and then "spraying" their surfaces with particles of an inorganic material. The invention also relates to hybrid lipid particles, uses and products, characterized in that the inorganic material particles are present on and in the lipid particles instead of being encapsulated by the lipid particles, and the active ingredient does not need to be encapsulated.
Resumen de: EP4559894A1
The present application relates to an amino lipid compound having the following structural formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and use thereof as a component of a lipid nanoparticle preparation for delivering a therapeutic agent. The present application further relates to a composition comprising the amino lipid compound, and particularly, to a lipid nanoparticle, and use thereof.
Resumen de: EP4559898A1
The invention relates to novel ionizable amine lipids incorporating one or more sulphur atoms in the tail section. These lipids can be used in combination with other components to form lipid nanoparticles with oligonucleotides. The invention describes the synthesis of the lipids of formula (I), formation and characterization of nanoparticles and biological experiments demonstrating that the lipid nanoparticles prepared with these novel lipids can efficiently deliver their cargo (e.g. RNA, DNA, mRNA, siRNA, miRNA, pDNA, circular DNA, dsRNA, small biologically active molecules) into the cells.
Resumen de: WO2024018364A1
Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.
Resumen de: CN120040543A
本发明涉及胸腺靶向肽基可离子化脂质及其纳米颗粒。更具体而言，本发明涉及肽基可离子化脂质、包含其的胸腺靶向的脂质纳米颗粒及其用途。
Resumen de: CN120037202A
本发明公开了一种基于连接处含有分支结构的阳离子脂质的脂质纳米颗粒及其应用，属于医药技术领域。所述所述脂质纳米颗粒的原料组成包括：连接处含有分支结构的阳离子脂质、辅助脂质、胆固醇，所述阳离子脂质的结构式如式(Ⅰ)所示。本发明提供的基于连接处含有分支结构的可电离阳离子脂质的脂质纳米颗粒，可以在动物体内有效地递送如mRNA等核酸类药物。相较于市售的可电离脂质SM‑102及其配方，本发明提供的脂质纳米颗粒在动物体内具有更好的mRNA递送效率，有利于改善mRNA等核酸药物的临床应用效果。
Resumen de: AU2023359279A1
Provided are an amino lipid compound for preparing a lipid nanoparticle for delivering an active ingredient and a preparation method therefor, a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and the use thereof.
Resumen de: CN120037201A
本发明公开了一种具有内质网靶向及免疫激活功能的聚合物‑金属离子复合物纳米颗粒，所述含氧化三级胺的两性离子聚合物的结构式为I所示#imgabs0#，其中，X为聚合单元，包括但不限于（甲基）丙烯酸酯（或）酰胺，氨基酸等；Y为N‑氧化三级胺连接基团，R1和R2选自甲基、乙基、丙基、丁基、戊基、己基，n=3‑300；所述具有免疫激动剂功能的为金属离子，金属离子选自锰离子、钙离子、锌离子、铁离子、铂离子中的一种。本发明将纳米颗粒有效递送至内质网并激活cGAS‑STING通路，增强抗肿瘤免疫反应，抑制肿瘤生长。
Resumen de: CN120037370A
本发明提供一种GSH响应型限域聚集金纳米囊泡及其制备方法和在放射增敏中的应用，所述金纳米囊泡为介孔二氧化硅包被AuNP@MnO2Ve@mSiO2，通过在AuNPs表面原位形成具有GSH响应性的MnO2，得到AuNP@MnO2；接着在AuNP@MnO2表面修饰上磷酸‑聚苯乙烯嵌段共聚物P‑PS；然后将其进行自组装，获得等离子体金纳米囊泡AuNP@MnO2Ve；最后用介孔二氧化硅包覆在AuNP@MnO2Ve表面进行修饰稳定，最终得到GSH响应型限域聚集金纳米囊泡AuNP@MnO2Ve@mSiO2；所述金纳米囊泡在放射治疗增敏剂中的应用。本发明制备的纳米金囊泡通过优化AuNPs的颗粒大小，特别是可通过GSH响应限域聚集策略改变AuNPs颗粒间的间距，增强其放射增敏效果，从而减少放疗辐射剂量，可有效地较少肿瘤细胞的放射抗性，避免X射线损伤相邻的正常组织。
Resumen de: CN120037375A
本发明提供了一种pH和光热双响应性聚多巴胺纳米载药微球及其制备方法和应用，涉及医药技术领域。本发明提供的pH和光热双响应性聚多巴胺纳米载药微球，包括疏水性药物、包覆所述疏水性药物的聚多巴胺和接枝在所述聚多巴胺表面的聚甲基丙烯酸N,N‑二甲基氨基乙酯。该载药微球利用肿瘤微环境酸性与正常生理条件的pH差异设计，不依赖肿瘤特异性抗原，因此具有广泛的适用性和较低的脱靶风险。本发明提供的载药微球具有优异的pH和光热响应性及良好的生物相容性，其能够在具有酸性微环境的肿瘤部位聚集并迅速释放药物，达到靶向治疗的目的，具有靶向肿瘤的普遍适用性；同时在局部近红外光照射下，发挥光热治疗作用，协同药物增强抑瘤作用。
Resumen de: CN120037203A
本发明公开了一种载SOX9siRNA脂质纳米粒，该脂质纳米粒由肿瘤靶向载体材料和SOX9siRNA组成。其中，所述的肿瘤靶向载体材料由cRGDfK肽修饰的磷脂‑聚乙二醇2000(DSPE‑PEG2000‑cRGDfk)、4‑(N,N‑二甲基氨基)丁酸(二亚油基)甲酯(DLin‑MC3‑DMA)、二硬脂酰磷脂酰胆碱(DSPC)、二肉豆蔻酰甘油‑聚乙二醇2000(DMG‑PEG2000)和胆固醇组成。本发明制备的载SOX9siRNA脂质纳米粒能被结直肠癌细胞摄取，实现溶酶体逃逸，抑制结直肠癌细胞的增殖、迁移和侵袭。同时在结直肠癌荷瘤小鼠体内也具有良好的肿瘤靶向性、抗肿瘤活性和安全性。
Resumen de: CN120037204A
本发明涉及了具有光热‑相变双功能核壳纳米粒的制备方法及其胞内递送应用，属于纳米材料和细胞递送领域。本发明提供一种应用于细胞胞内递送生物大分子的具有光热‑相变双功能核壳纳米粒，所述的纳米粒为核壳结构，以高分子聚合物为外壳，以液态氟碳和光热材料为内核，采用超声乳化法制备而成，制备方法简单。由于液态氟碳沸点低，光热材料具有良好的光热转换性能，因此所述核壳纳米粒在激光诱导下可以快速产生光热蒸汽微泡。在激光与核壳纳米粒的协同作用下，诱导产生的蒸汽微泡在植物细胞壁和细胞膜或动物细胞膜上产生微孔，从而克服细胞壁与细胞膜的物理屏障，显著提高向细胞内递送外源功能生物大分子的效率。
Resumen de: CN120037229A
本发明公开了一种提高花青素稳定性的纳米复合物的制备方法，包括将紫玉米花青素溶解于蒸馏水中；将壳寡糖溶解于蒸馏水中；将壳寡糖溶液滴加至花青素溶液后，经磁力搅拌混合均匀后逐滴加入聚磷酸盐溶液，反应后将混合液转移至离心管中离心10‑30分钟，以分离出纳米复合物沉淀和未结合的上清溶液，之后加入超纯水重复离心。最后，将沉淀物真空冷冻干燥处理，得到一种提高花青素稳定性的纳米复合物。本发明方法制备的纳米复合物具有更高稳定性、良好分散性和增强的生物活性，能够形成稳定的三维网状结构，纳米复合物粒径小，且分布较为均匀，为壳寡糖与花青素在食品、化妆品及生物医药等领域的广泛应用提供了新途径。
Resumen de: CN120040464A
本发明提供了一种新型可电离脂质分子的制备和应用，该分子包含二硫键和异甘露醇结构，利用这种可电离脂质分子制备的脂质纳米粒(LNPs)具有出色的包封效率，并能够显著提高将药物递送至细胞和动物的效率。含有二硫键和异甘露醇结构的可电离脂质分子制备的脂质纳米粒能提高其在生物体内的稳定性、相容性和安全性，所述脂质纳米粒不仅能够调控药物的活性，增加药物稳定性以及提高生物对药物的利用度，而且为核酸药物提供了一种高效的递送途径，从而推动核酸药物的发展。
Resumen de: AU2023350778A1
Provided are novel sulfur-containing lipids and nanoparticles containing such lipids and a cargo molecule, such as a nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making said lipids. The lipids may have the structure of Formula A as defined herein. Formula A
Resumen de: CN120037371A
本发明属于诊疗载药超顺磁纳米颗粒制备技术领域，具体涉及胶质瘤诊疗用双靶向载药超顺磁纳米颗粒的合成方法，所述合成方法包括以下步骤：S1：进行RexFe3‑xO4的制备与表征；S2：进行Yb0.015Fe2.985O4@PEI‑HA的制备与表征；S3：进行MET@Yb0.015Fe2.985O4@PEI‑HA的制备与表征；S4：对MET@Yb0.015Fe2.985O4@PEI‑HA体外抗肿瘤效果进行分析；S5：对MET@Yb0.015Fe2.985O4@PEI‑HA体内MRI‑T2成像效果进行分析。本发明能够采用MHT‑PDT‑CDT三种治疗模式协同治疗，同时通过MET和磁热增强肿瘤细胞自噬和铁死亡能力。
Resumen de: CN120037205A
本发明公开了一种环黄芪醇‑花型乳糖纳米颗粒及其新用途，环黄芪醇‑花形乳糖颗粒能够有效抑制炎症细胞浸润及炎症因子基因表达水平升高引起的心肌纤维化；抑制心肌纤维引起的心肌胶原容积分数增高、心肌纤维化标志基因表达水平升高及心肌组织中ANF基因表达水平上调。环黄芪醇‑花形乳糖颗粒能够明显改善由CVB3感染诱导的实验小鼠心肌纤维化程度，在心肌纤维化的防治中有良好的应用前景。
Resumen de: CN120037206A
本发明提供一种巨噬细胞膜修饰的MPDA@CeO2仿生纳米复合体的制备方法及其在急性肺损伤中的治疗应用，该纳米复合体应用仿生学原理设计了一种新型的纳米材料，成功将提取的巨噬细胞膜微囊包覆在介孔聚多巴胺负载的二氧化铈纳米复合体表面，通过将介孔聚多巴胺及二氧化铈的优异抗氧化功能相结合，实现对肺部炎症部位的主动靶向，通过从而减轻过量的活性氧聚集，缓解过度的炎症反应，从而有效改善急性肺损伤的氧化应激和过度炎症等病理状态，对炎症性疾病均具有治疗推广的临床转化应用作用。
Resumen de: CN120022257A
本发明公开了一种负载有雷公藤红素的多级金属有机框架仿生纳米酶及其制备方法和应用，属于纳米药物技术领域，方法包括：（1）以铁氰化钾、聚乙烯吡咯烷酮和盐酸为原料制备普鲁士蓝纳米颗粒；（2）制备组分包含普鲁士蓝纳米颗粒和聚乙烯吡咯烷酮的甲醇溶液，依次加入2‑甲基咪唑和锌源反应后，得到以普鲁士蓝纳米颗粒为内核，ZIF‑8聚集层为外壳的复合纳米颗粒；（3）使雷公藤红素负载于复合纳米颗粒的ZIF‑8聚集层上，得到载药复合纳米颗粒，利用巨噬细胞膜包覆载药复合纳米颗粒，得到负载有雷公藤红素的多级金属有机框架仿生纳米酶。该仿生纳米酶在重症胰腺炎治疗方面具有广阔的应用前景。
Resumen de: CN120022347A
本发明属于药物制剂技术领域，具体涉及一种源自灵芝的蛋白口溶膜及其制备方法和应用。所述的源自于灵芝的蛋白口溶膜按质量百分含量计，包括以下原料：小孢子灵芝免疫蛋白(Ganoderma microsporum immunomodulatory protein，GMI)1‑10％、成膜材料25％‑50％、增塑剂5％‑20％、黏膜黏附剂5％‑30％、促渗剂1％‑20％、矫味剂5％‑20％、着色剂0.1％‑1％和酸度调节剂0.5％‑3％。本发明通过对配方组分种类及其配比的优化，不仅确保口溶膜具有优良的外观质量，还具备较好的耐折性和较短的崩解时间，进一步提升产品的使用体验。
Resumen de: WO2024094125A1
Provided herein are lipid compounds, e.g., a compound of Formula (I). Also provided are lipid nanoparticles and pharmaceutical compositions, each comprising a lipid compound, e.g., a compound of Formula (I).
Resumen de: CN120022254A
本发明提供壳聚糖包裹吸附穿心莲内酯和绿原酸的银纳米颗粒、制备方法及其应用，涉及生物医学技术领域，其中制备方法如下：将PEI‑AgNPs置于离心管中离心弃去上清，将获得的沉淀物干燥；取沉淀物加入到离心管中，加入DMSO，然后加入AG和CA溶于离心管中，室温避光搅拌后离心，离心完成后取上清；再加入DMSO，洗涤，完成后收集所得上清，将沉淀干燥；将CS溶于醋酸溶液中后加入上述沉淀。本申请中综合了Ag+、穿心莲和银杏叶的特点，将穿心莲内酯和绿原酸与Ag+结合，并且利用天然粘合剂壳聚糖进行包裹，发现不仅能抑制大肠杆菌和金黄色葡萄球菌的生长，也能通过抑制NF‑κB信号通路和激活PI3K‑AKT信号通路来降低伤口活性氧和炎症因子的水平，促进皮肤伤口愈合。
Resumen de: CN120022386A
本发明公开了一种酸响应共轭聚合物ZnO复合纳米材料及其制备方法与应用，属于有机‑无机杂化纳米材料技术领域。所述酸响应共轭聚合物ZnO复合纳米材料可用于肿瘤的荧光成像及声动力学治疗。ZnO量子点能够通过电荷转移猝灭共轭聚合物的荧光和声动力学性能，正常环境下，所述酸响应共轭聚合物ZnO复合纳米材料中共轭聚合物的荧光发射和声动力学性能被抑制，但在肿瘤酸性环境下实现激活响应，ZnO分解使共轭聚合物的荧光和声动力学性能恢复，同时释放的Zn2+可以诱导细胞焦亡在一定程度上提高肿瘤的治疗效果。
Resumen de: WO2024086512A1
Methods and systems for analyzing lipid nanoparticles using size exclusion chromatograph coupled with multi angle light scattering are disclosed.
Resumen de: CN120022255A
本发明提供了一种增强铁死亡和激活免疫反应的联合纳米药物及其制备方法和用途，属于生物药物领域。本发明联合纳米药物(HH‑PP)是由HH‑PTX和HH‑Ppa共组装制备而成；HH‑PTX和HH‑Ppa的质量比为1:4～4:1。本发明制备的HH‑PP治疗时采用激光照射，能够诱导肿瘤细胞铁死亡，激活免疫反应，从而抑制肿瘤细胞增殖，发挥抗肿瘤效果。此外，HH‑PP具有良好的生物安全性。因此，本发明制备的联合纳米药物HH‑PP具有良好的临床应用前景。
Resumen de: CN120022371A
本发明属于生物医药领域，具体涉及一种作为无材料载药体系的有机分子自组装体及其制备方法和用途。本发明提供了一种自组装体，该自组装体由类固醇系列分子构成，通过优选这些类固醇的分子结构及其临界聚集浓度，制备得到类固醇系列分子自组装形成的无材料载药体系。该无材料载药体系可以装载药物，制备药物纳米复合物。该纳米复合物中，药物的药效得到提高，能够实现“减毒增效”的效果。进一步的，若所用的类固醇分子本身具有生物活性，则其制成药物纳米复合物后，类固醇分子本身的药理活性未受到影响。本发明制备的无材料载药体系具备无载体和以传统材料为载体的两种纳米制剂的优势，在开发新型纳米药物制剂方面，具有良好的前景。
Resumen de: CN120022383A
本发明涉及生物医药领域，特别是涉及一种介导细胞焦亡的核酸药物组合物及其应用。本发明中核酸药物组合物包含可电离脂质化合物和GSDM蛋白家族基因的mRNA。本发明中编码GSDM蛋白家族的mRNA在包含特定结构可电离脂质的LNP系统协助下，在体内被翻译成GSDM蛋白，触发细胞焦亡。细胞焦亡能够诱导细胞死亡，启动促炎细胞因子的释放，激活和募集体内的免疫细胞，进而引发一系列级联反应事件，进一步促进细胞死亡、细胞因子释放和免疫激活，且和市售产品相比，本发明特定结构的可电离脂质表现出更为优异的介导细胞焦亡效果，为细胞焦亡相关领域提供了一种全新的具有临床转化潜能的治疗手段。
Resumen de: CN120025256A
本发明公开了一种含氮链状化合物、制备方法、包含其的组合物和应用，具体地，本发明提供了一种化合物I或其药学上可接受的盐，采用本发明的含氮链状化合物制备得到的LNP制剂，纳米颗粒大小相对均匀，包封率较高，体内表达活性较高。#imgabs0#
Resumen de: CN120022252A
本发明提供一种杂化二氧化硅涂层的药物递送载体及其制备方法和应用，所述药物递送载体为表面沉积有二氧化硅层的聚(乳酸‑羟基乙酸)纳米颗粒，即SiLGA NPs，并通过实验验证了该纳米颗粒能够作为可行的药物递送载体，其具有低于200nm的直径，亚稳的Zeta电位，高负载效率和含量；与未被二氧化硅涂层包被的PLGA NPs相比，SiLGA NPs更大程度上保留了酶的活性，由于包封酶保留了很好的活性，能够催化小分子底物通过多孔二氧化硅层扩散；具有良好的应用前景。
Resumen de: CN120022256A
本发明涉及医用、牙科用或梳妆用的配制品技术领域，尤其涉及一种具有吸附肠道黏膜作用的微胶囊及其制备方法。与现有技术相比，本发明通过对壳聚糖进行改性，从而其表面引入游离硫醇基团，经交联得到包材，再与活性成分进行包埋得到微胶囊，该微胶囊能够改善黏膜粘附并延长保留时间，使得药物在消化道内滞留时间延长，提高药物生物利用度。
Resumen de: WO2023244803A1
This application relates in part to nanoparticles comprising a tobamovirus and nanoparticles comprising a tobamovirus and beta-cyclodextrin (β-CD or BCD). This application also relates in part to nanoparticles comprising tobamovirus and one or more active ingredients (AIs) that are non-covalently conjugated to the tobamovirus. The application also provides methods of making and methods of using such nanoparticles as well as compositions comprising the disclosed nanoparticles.
Resumen de: CN120021771A
本发明提供了一种负载β‑胡萝卜素的醇化Pickering乳液及其制备方法和应用，属于食品加工技术领域。本发明首先制得乳蛋白‑醇溶蛋白复合纳米颗粒溶液；对多糖溶液进行醇化处理和调节pH值后，与乳蛋白‑醇溶蛋白复合纳米颗粒溶液进行混合处理，得到蛋白质‑多糖复合颗粒的溶液；将β‑胡萝卜素的油相溶液与蛋白质‑多糖复合颗粒的溶液进行剪切均质处理，得到负载β‑胡萝卜素的醇化Pickering乳液。本发明制备的乳液中蛋白质‑多糖复合颗粒牢固、不可逆地吸附在油水界面上，形成了致密的界面层，并提供足够的空间位阻和静电排斥力，提高了β‑胡萝卜素的包埋率、光和热稳定性，有效抑制促氧化剂向油相扩散速率，提高了β‑胡萝卜素稳定性和生物可及性。
Resumen de: CN120022253A
本发明公开了一种用于超声激发铜死亡的有机聚合物复合纳米材料及其制备方法与应用，属于纳米材料和生物医疗技术领域。本发明合成的有机聚合物复合纳米材料由纳米球壳包裹声敏剂和铜死亡药物，声敏剂在超声情况下可以快速产生单线态氧，不仅可以诱导肿瘤细胞凋亡，而且还可以使得纳米球壳中的硫醚键响应断裂解体，使得纳米球壳中的铜死亡药物ESCu释放，实现声动力与铜死亡协同作用，从而杀死肿瘤细胞。
Resumen de: CN120022294A
本发明公开了一种用于肺纤维化治疗的工程化多能巨噬细胞的制备方法，包括M1‑l ike BMDM的获取、ABT@MP的制备和ABT@MP@M1的构建；M1‑l ike BMDM的获取包括步骤一：剥离雄鼠的骨质，冲出骨髓细胞，置于FBS的DMEM中培养；步骤二：每3天换液并补加诱导因子，7天后获得BMDM；向上述BMDM中添入刺激素，刺激24h，最终获得M1‑l ike BMDM；ABT@MP的制备包括步骤一：聚3‑羟基丁酸‑3‑羟基己酸酯和ABT‑263溶于二氯甲烷作为油相；步骤二：胆酸钠水溶液经滤器过滤除杂后作为水相；步骤三：油相在冰浴超声条件下逐滴加入水相以形成O/W乳液；本发明获取了高纯度的(≥97％)，表达iNOS、TNF‑α、IL‑6、IL‑12等M1型极化标志物的M1‑l ike BMDM；制备了平均粒径约为4μm，呈均一球形的负载衰老ACEⅡ清除剂ABT‑263的聚合物微米颗粒(ABT@MP)。
Resumen de: US2025161451A1
An ultrasound-responsive nanoscale delivery platform for use in treating biofilm-associated diseases is provided. The inventors have found that the use of a phase-shift nanodroplet/antimicrobial complex platform confers a number of advantages when used in methods for antibiofilm therapy. Specifically, the inclusion of antimicrobials within the supramolecular structure of the ultrasound-responsive nanoscale delivery platform allowed for increased passive cellular and subcellular uptake, stimuli-responsive spatiotemporally controlled drug release, and significantly higher bacterial toxicity in both planktonic cultures and mature biofilms. This platform remains stable in storage at room temperature, in blood components, and does not significantly prematurely release its loaded cargo. The platform may be used as a novel treatment option in biofilm-associated diseases such as, but not limited to, bone and joint infections, cystic fibrosis-associated pleural infections, chronic wounds, and chronic urinary tract infections.
Resumen de: WO2025104620A1
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Resumen de: US2025161432A1
The present application relates to the field of drug carriers, and specifically discloses a cationic lipid compound, and a preparation method therefor and a use thereof. The cationic lipid compound comprises a compound represented by formula I; in the formula I, n is equal to 1, 2, 3 or 4; R1 and R2 are each independently selected from secondary long-chain alkyl esters represented by formula II; in the formula II, n1=2, 4 or 6, n2=5, 7, 9 or 11, and n3=5, 7, 9 or 11. The cationic lipid compound is combined with phospholipids, cholesterol and polyethylene glycol lipids, such that an LNP carrier may be prepared, and then nucleic acid molecules are wrapped to prepare a corresponding drug. The raw materials for the production of the cationic lipid compound in the present application are easy to obtain, the synthesis steps are simple, the constructed LNP carrier has a good drug delivery effect, the corresponding drug can efficiently enter a target cell or activate an immune response of an organism, and thus the cationic lipid compound has practical application value.
Resumen de: US2025161498A1
The invention provides microbubbles and PSMB labeled with targeting ligands that are useful in the detection and treatment of vascular thromboses (e.g., fibrin clots) and vascular plaques, or related diseases and conditions, as well as methods of preparation and use thereof.
Resumen de: US2025161496A1
Described herein are synthetic promoters and/or enhancers that are specific for cancer cells and methods of engineering synthetic cancer-specific promoters.
Resumen de: US2025161491A1
Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.
Resumen de: WO2025104091A1
The present invention relates to functionalized nano- or microparticles of suitable size and shape, comprising a nano- or microparticle and at least one virus-binding peptide and/or virus-binding small molecule immobilized onto the surface of the nano- or microparticle. These nano- or microparticle forms aggregates with targeted viral particles to initiate phagocytosis, thereby achieving viral clearance. The present invention further relates to uses of the functionalized nano- or microparticles in virus detection, therapy and diagnosis.
Resumen de: US2025161481A1
Disclosed are lipid nanoparticle (LNP) delivery systems that specifically target T cells. The LNP delivery system comprises antibodies conjugated to the surface of the LNP, e.g., via maleimide chemistry, that target at least two T cell surface proteins, e.g., CD3 and CD28. The LNP delivery system can have a single population of LNP conjugated to either a bispecific antiCD3/antiCD28 antibody, or two monospecific antiCD3 and antiCD28 antibodies, or two populations of LNP wherein each population comprises a monospecific antibody. The payload of the LNP delivery system can be, e.g., mRNA encoding chimeric antigen receptors (CAR), a linear DNA fragment or a plasmid encoding chimeric antigen receptors (CAR) or therapeutic proteins such as antibodies, components of a gene editing systems (e.g., CRISPR-Cas), small molecules, antibody-drug conjugates (ADC), and any combination thereof, either encapsulated in the LNP or attached to its surface (e.g., conjugated). Also provided are lipids, pharmaceutical compositions, kits, and methods of treatment.
Resumen de: US2025161480A1
The present invention relates to the technical field of biomedicines and vaccines, and in particular to an aluminum nanocrystalline composite immune drug and a preparation method therefor and use thereof. The aluminum nanocrystalline is used as a carrier, the surface of the aluminum nanocrystalline is covered with polyethylene glycol, and functional polypeptide sequences and cytokine molecules are linked by a polyethylene glycol end group to form a virus-like particle immune drug. According to the drug, the cytokine stability and the tumor tissue retention time are improved, and the auxiliary anti-tumor effect of the cytokines is effectively improved.
Resumen de: US2025161533A1
Provided herein are bioresorbable, bioregenerative composite materials and compositions to regenerate tissues or organs to repair tissue or organ defects and constructs printed from the same as 3D structures shaped and sized to fill a tissue or organ defect. The composite materials are bioresorbable polymers, for example, polycaprolactone, and a bioresorbable graft material, for example, demineralized bone matrix. Also provided are methods for making the composite materials and compositions and methods for regenerating tissues or organs and repairing a tissue or organ defect using the constructs.
Resumen de: US2025161434A1
Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.
Resumen de: US2025161462A1
The disclosure provides for compounds and compositions comprising hydrophilic-masked cationic charge dendrimers, and applications thereof, including delivering siRNA, ASO, PMO, PNA, oligonucleotide and nucleic acid vectors. The methods and approaches disclosed herein can also be applied to lipids to make hydrophilic-masked cationic charge lipid nanoparticles for mRNA, RNA, siRNA, DNA, ASO, PMO, PNA, oligonucleotide and nucleic acid vector delivery.
Resumen de: US2025161400A1
Bioavailable compositions comprising nanoparticulated ingredients in aqueous solution, methods of making the same, and methods of administering the same. A method includes providing an effective amount of a composition to an animal to reduce oxidative stress in the animal. The composition includes a water solvent and a nanoparticulated ingredient, wherein the nanoparticulated ingredient comprises one or more of nanoparticulated glutathione, nanoparticulated l-cysteine, nanoparticulated curcumin, or nanoparticulated collagen.
Resumen de: US2025161350A1
The invention relates to shape-specific cerium oxide nanoparticles (CNPs). methods of preparing CNPs. and methods of using CNPs to treat and/or inhibit and/or reduce and/or reverse the complications of respiratory syncytial virus (RSV) disease and other infections that cause pathologic immune responses. through the balance of favorable immunomodulation and reduced lung immunopathology. CNPs have the capability to switch between Ce3+ and Ce4+ oxidation states (e.g., to scavenge reactive oxygen species). The shape-specific CNPs are synthesized into various shapes and sizes. These properties offer an opportunity to utilize CNPs to modulate macrophage phenotypes along the spectrum of M1 and M2 phenotypes to combat RSV infection and other infections that cause pathologic immune responses.
Resumen de: WO2025106912A1
Gas-bubble based degrading liquid foams to deliver nucleic acids are disclosed. The nucleic acids can be delivered for a variety of research, diagnostic, and therapeutic uses, such as in situ CAR T and stem cell engineering. The foams can also be used for administration of therapeutic nucleic acids to anatomical sites, such as cancer sites, through direct application at the site or through the use of edible or drinkable foams in the case of esophageal cancers, the use of rectally applied foams to treat rectal or colorectal cancer, or the use of intraperitoneally injected foam to treat widespread ovarian cancer. The nucleic acids can be delivered in a vector, such as a lipid nanoparticle or a viral vector.
Resumen de: WO2025106590A1
A modified myoferlin protein capable of being packaged into extracellular vesicles (EVs) to facilitate release of EV payloads into recipient cells. The modified myoferlin protein enhances the release of payload at the targeted site. The present invention further provides a modified myoferlin-encapsulating nanoparticle comprising an exosome encapsulating any embodiment of the modified myoferlin of the present invention and one or more cargo RNAs to enhance release of the cargo RNAs at the targeted site.
Resumen de: WO2025106045A1
The invention relates to a dissolving microneedle containing nanoparticles loaded with a Receptor-Binding Domain (RBD).
Resumen de: WO2025103414A1
The present invention relates to a preparation method for and the use of lipid nanoparticles. Specifically, provided is a freeze-dried composition, comprising lipid nanoparticles and sodium chloride, wherein the lipid nanoparticles comprise at least one cationic lipid, and the weight ratio of sodium chloride to the cationic lipid is 1:10-10:1
Resumen de: WO2025103396A1
A pharmaceutical composition comprising a nucleic acid construct and the medical use thereof. Specifically, the present invention relates to a lipid nanoparticle comprising a nucleic acid construct represented by formula I, which can achieve highly efficient delivery of a exogenous target gene, allowing the exogenous target gene to be highly efficiently and rapidly expressed in the body. The present invention has the advantages of no gene integration risk and being easy to scale up to an industrial level, is a more ideal treatment approach than naked plasmids, and can be used as a gene therapy drug for a plurality of diseases.
Resumen de: WO2025102910A1
A biotin or avidin-labeled fat body, a preparation method therefor, and a nano-carrier system. A specific amount of bio-phospholipid or avidin-phospholipid is used to prepare a biotin or avidin labeled fat body. The prepared fat body has the advantages of high purity, small particle size, good uniformity and high stability. A nano-carrier system is constructed on the basis of the biotin-avidin system, and the nano-carrier system comprises the biotin-labeled fat body and an avidin-modified target component. By utilizing the system, the fat body can carry any substance of interest, for example protein drugs such as virus recombinant proteins, and antibodies, nucleic acid drugs or small molecule drugs, thereby being used for vaccines and the treatment of diseases such as cancers, infectious diseases and metabolic diseases.
Resumen de: WO2025102670A1
A nanoparticle adiposome encapsulating a hydrophobic small-molecule drug, a preparation method therefor, and a use thereof. The nanoparticle adiposome encapsulating the hydrophobic small-molecule drug comprises a monomolecular phospholipid membrane and hydrophobic small-molecule drug-containing neutral lipids encapsulated within the monomolecular phospholipid membrane. The nanoparticle adiposome has the hydrophobic small-molecule drug-containing neutral lipids as a hydrophobic core, and nanobeads wrapped by the monomolecular phospholipid membrane can efficiently dissolve and encapsulate a hydrophobic small-molecule compound. In addition, the adiposome encapsulating the hydrophobic small-molecule drug has bioactivity, can remarkably kill cancer cells, and has a killing effect superior to that of a free drug. In addition, the preparation method is simple and efficient. Therefore, the adiposome is a prospecting hydrophobic small-molecule drug delivery platform, and can be widely applied to the treatment of diseases such as cancer, infectious diseases and metabolic diseases.
Resumen de: WO2025102275A1
A preparation method for an engineered extracellular vesicle targeting oncofetal chondroitin sulfate-positive cells, and the use of same, belonging to the technical field of biomedicines. The present invention provides an engineered extracellular vesicle targeting oncofetal chondroitin sulfate-positive cells, which is obtained by collecting a supernatant of cells that stably overexpress a protein containing ofCSbps and separating same, the sequence of the ofCSbps being one of or a combined polypeptide sequence of more than one of SEQ ID NO. 1-7, or a derived sequence taking one polypeptide sequence of SEQ ID NO. 1-7 as a backbone, or a derived sequence taking a combined polypeptide sequence of more than one of SEQ ID NO. 1-7 as a backbone. The engineered extracellular vesicle of the present invention has the characteristic of targeting ofCS-positive cells. Since extracellular vesicles have nanoscale liposome encapsulation structures, the present invention is suitable for basic research and clinical diagnosis and treatment application on various diseases, such as placenta-derived physiological/pathological and tumor/cancer diseases, in humans and animals.
Resumen de: WO2025102261A1
Lipid compounds for delivering a therapeutic agent, a preparation method therefor and the use thereof. The lipid compounds are compounds with structural formula (I) or pharmaceutically acceptable forms thereof. The lipid compounds may be used in combination with other lipid components, such as neutral lipids, cholesterol, and polymer-bound lipids, so as to form lipid nanoparticles used for delivery of therapeutic agents (e.g. nucleic acid molecules) to achieve therapeutic or prophylactic purposes (e.g. vaccination), thus enriching the types of ionizable lipid compounds.
Resumen de: WO2024133486A1
The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in preventing and/or treating a disease, in particular for use in preventing and/or treating cancer. The present invention furthermore pertains to a method for producing a composition comprising said nucleic acid-lipids particles.
Resumen de: AU2025203126A1
Disclosed herein are stereocomplexes for the delivery of one or more anti cancer agents. The stereocomplexes exhibit low toxicity and are biodegradable while also providing for controlled release of one or more anti-cancer agents at tumor sites. The stereocomplexes can be designed such that the anti-cancer agents operate synergistically and may optionally include additional targeting groups and functionalities. The stereocomplexes disclosed herein can be combined with pharmaceutically-acceptable carriers and/or excipients to form pharmaceutical compositions. By varying the amount of each anti-cancer agent in the stereocomplex, specific types of tumors and cancer cell lines can be treated.
Resumen de: AU2023357035A1
The present invention relates to cell permeant particles. In particular, the present invention relates to plasma-treated particles or plasma-synthesised particles that are capable of migrating across the membranes of live cells.
Resumen de: AU2023382803A1
The present invention relates to a nanoparticle composition for drug delivery and, more specifically, to a composition for drug delivery, wherein the composition comprises an amphiphilic block copolymer and a lipid with a specific structure that can easily form complexes with anionic drugs, whereby the composition can easily form drug-containing nanoparticles and thus is useful for drug delivery, especially for targeted delivery of drugs to the lungs.
Resumen de: AU2023385485A1
The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat various disorders.
Resumen de: AU2023385479A1
Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by 3-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.
Resumen de: AU2023375580A1
Provided herein are compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed by the aggregation of misfolded transthyretin (TTR) proteins. Such conditions include, but are not limited to, polyneuropathy due to hereditary transthyretin amyloidosis (hATTR-PN) and hereditary cardiomyopathy due to transthyretin amyloidosis (hATTR-CM), both associated with autosomal dominant mutations of the TTR gene, and an age-related cardiomyopathy associated with wild-type TTR proteins (ATTRwt), also known as senile cardiac amyloidosis.
Resumen de: AU2023364999A1
Novel compositions of TCR Gamma Alternate Reading Frame Protein (TARP) peptides combined with cationic lipids such as the DOTAP and specifically R-DOTAP, induce high levels of TARP-specific polyfunctional cytolytic T-cells. Compositions and methods of use are provided. The compositions comprise N-terminal and C-terminal overlapping peptide sequence pairs duplicating the critical central antigenic region of TARP and encompassing the entire protein selected and designed to be effectively processed by antigen-presenting cells to prime cytotoxic T cells specific for TARP-derived T cell peptide antigens when delivered in combination with immunostimulatory nanoparticles composed of R-DOTAP cationic lipids.
Resumen de: US2025161228A1
The disclosure provides compositions including ultrafine bubbles having water and gases released from solution in the water. The compositions may dissolve, surround, and/or stabilize one or more non-gaseous solutes. Methods of making and using the compositions for delivering an active pharmaceutical ingredient to cells are also provided. The methods of making the compositions including ultrafine bubbles include processes for dissolving, surrounding, and/or stabilizing non-gaseous solutes and/or active pharmaceutical ingredients with ultrafine bubbles. Methods of using the compositions to produce active pharmaceutical ingredients and/or increase yield thereof via fermentation are also provided.
Resumen de: US2025161220A1
Provided herein are composition, systems, kits, and methods for preventing and/or treating, reversing, and/or inhibiting progression of, a neurodegenerative and/or neurological conditions and/or eye conditions (e.g., retinitis pigmentosa) by administering a plurality of nanoparticles to a subject via subcutaneous, intramuscular, or intraperitoneal injection such that the plurality of nanoparticles are taken up by lymphatic capillaries and are transported to neurological and/or eye tissue of the subject via the subject's lymphatic system, wherein the plurality of nanoparticles encapsulate, or are attached or absorbed to, at least one drug agent.
Resumen de: US2025161216A1
A cationic lipid analogue, a composition and a use thereof. An aldehyde, an amine, a carboxylic acid and an isonitrile are adopted as raw materials to synthesize a cationic lipid analogue via the Ugi reaction. The synthesized cationic lipid analogue, together with a sterol, an auxiliary lipid and a polyethylene glycol lipid derivative, further forms a nanoparticle-like lipid composition, which can be used for drug delivery, including the delivery of small molecule drugs, nucleic acid drugs such as mRNA, DNA, siRNA, etc., protein/peptide drugs, and gene editing complexes such as mRNA/sgRNA, Cas9/sgRNA, etc. The nanoparticle-like lipid composition achieves mRNA expressions in different organs of animals through different administration methods, and thus can meet the application requirements of mRNA nucleic acid therapies, nucleic acid vaccines, gene editing, etc.
Resumen de: US2025161219A1
The methods of manufacture of a drug delivery composition. In some aspects, the methods include providing an organic phase, a biologically active ingredient, and an aqueous phase with a desirable pH (e.g., a pH at which the active ingredient has increased solubility in the aqueous phase compared to at neutral pH). After mixing of one or more of the aforementioned components, the resultant mixture is processed to provide the desired drug delivery composition.
Resumen de: US2025161226A1
The present invention relates to the technical field of biopharmaceutics and vaccines, and in particular, to an aluminum-based self-assembled delivery system for mRNA, a method for preparing same, and use thereof. The aluminum-based self-assembled delivery system for messenger RNA is a nanocrystallite formed by in-situ self-assembly of an aluminum ion, an mRNA, and a co-assembled molecule driven by coordination. The delivery system serves as a vector-free self-delivery system serving for interleukin 21 mRNA, and can achieve efficient delivery of interleukin 21 mRNA and improved mRNA stability and targeted mRNA delivery efficiency. The nanoparticle of the present invention features good stability in serum and low toxicity, and can achieve efficient mRNA transfection in melanoma cells and significant inhibition of tumor growth in a melanoma mouse model. Therefore, the present invention provides an efficient and convenient preparation method for nucleic acid delivery systems, and has extremely high practical value.
Resumen de: US2025161227A1
Compounds are provided having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein R1, R2, R3, m, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: US2025161214A1
Provided herein are dried compositions and methods for preparing such compositions for use in delivery of a nucleic acid to a subject. The dried composition may comprise a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, optionally one or more inorganic nanoparticles and one or more lipids, one or more nucleic acid, and at least one cryoprotectant. Methods of using these dried compositions for treatment are also provided.
Resumen de: US2025161217A1
A multi-layer niosome nanocarrier drug composition for optimized drug delivery is described herein. The composition comprises chloroform extract of mint, Kaempferol Iodine-127 in the inner layer, and fulvic acid in the outer layer of the niosome. The method of preparing the composition is also described herein and may involve dissolving components in chloroform and incubating kaempferol-iodine-loaded niosomes in fulvic acid. The process ensures efficient drug release and enhanced therapeutic efficacy.
Resumen de: US2025161221A1
Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
Resumen de: US2025161425A1
Provided herein is a nucleic acid (e.g., messenger RNA) vaccine encoding at least one antigenic prokaryotic polypeptide linked to one or both of a viral secretion signal peptide and a transmembrane domain. Also provided are methods of vaccination against a prokaryotic infection with the nucleic acid described herein.
Resumen de: US2025161295A1
Formulations for treating proliferative disorders have been developed. In some forms, the formulations are in the form of an injectable aqueous solution for treating tumors and contain exatecan mesylate, optionally including an immunostimulatory agent or adjuvant such as an immunostimulatory oligonucleotide (CpG), at a pH at which the exatecan is soluble until the pH is raised by contacting normal tissue. In some forms, the formulations contain core-shell particles, containing an exatecan in its free base form, a hydrophobic core, and a shell, coating, or corona containing hyperbranched polyglycerol in which hydroxyl groups of the hyperbranched polyglycerol are converted to aldehydes, to adhere the particles to tissue.
Resumen de: US2025163126A1
Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering—an onerous barrier for traditional receptor targeting strategies.
Resumen de: US2025162978A1
The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.
Resumen de: US2025162981A1
Disclosed are lipidoid compounds having the structure of formula (I), or a pharmaceutically acceptable salt thereof:wherein the groups are as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses pharmaceutical compositions comprising a lipidoid composition of the invention.
Resumen de: US2025161331A1
The disclosed formulations include Diclofenac Sodium Salt and at least one cannabinoid. Other formulations include other anti-inflammatory drugs such as methotrexate and prednisone, for example. In addition, methods of using formulations to treat diseases or disorders such as arthritis, pain, inflammation and fever are disclosed.
Resumen de: US2025161940A1
Limit size lipid nanoparticles, methods for using the lipid nanoparticles, and methods and systems for making limit size lipid nanoparticles.
Resumen de: WO2025106806A1
Compounds are provided having the following Formula (I): (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein R1, R2, R3, m, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: WO2025104695A1
Provided herein are ionizable lipids of the following structural formula: (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein values for the variables (e.g., G1, G2, L1, L2, M1, M2, R1, R2, R3, R4) are as described herein. Also provided are lipid nanoparticles comprising ionizable lipids of Formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and methods of using the ionizable lipids, e.g., to administer therapy to a subject in need thereof.
Resumen de: WO2025106670A1
Disclosed are lipidoid compounds having the structure of formula (I), or a pharmaceutically acceptable salt thereof: formula (I) wherein the groups are as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses pharmaceutical compositions comprising a lipidoid composition of the invention.
Resumen de: WO2025106874A1
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a disorder-related polypeptide. Also provided are methods to treat various neurodegenerative disorders. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions and kits for expressing a disorder-related polypeptide in an individual in need thereof.
Resumen de: US2025161437A1
The present invention relates to modular nanoparticle-based compositions comprising immune response modulating molecules, which are particularly useful in prophylaxis and/or treatment of diseases and disorders wherein a specific type of immune response to an antigen is desired.
Resumen de: AU2023308644A1
Described herein are milk exosomes and uses thereof. In some embodiments, the milk exosomes are capable of targeting an injury site or a cancer cell or population thereof. The milk exosomes can contain an exogenous cargo. Described herein are formulations containing the milk exosomes, and optionally, a targeting agent, such as IgG or stimulation of ATP concentration, and/or ADP. Also described herein are methods of delivering a cargo to a target.
Resumen de: WO2024015363A1
Methods for creating injectable sustained release nanocrystals to deliver antifibrotic drugs in a sustained fashion locally in tissue are described.
Resumen de: EP4556000A1
The present invention provides a lyophilized composition of nucleic acid-encapsulating lipid nanoparticles having a pH of 4.5 or more and 6.9 or less, including an ionic lipid represented by the formula (1):wherein symbols are as defined in the DESCRIPTION.
Resumen de: EP4556457A2
The present disclosure relates to cannabinoid compositions used in combination with stem cell therapies. These compositions can be encapsulated (e.g., microencapsulated). In particular, these compositions can be administered to a subject, such as through oral consumption or topical treatment.
Resumen de: EP4556460A1
An amino lipid compound, a preparation method therefor, a composition thereof and an application thereof. Specifically disclosed are an amino lipid compound represented by formula (I), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a use thereof in preparing a lipid nanoparticle for delivering an active ingredient, and a composition containing the amino lipid compound, especially a lipid nanoparticle, and a use thereof.
Resumen de: EP4556028A1
The present invention relates to functionalized nano- or microparticles of suitable size and shape, comprising a nano- or microparticle and at least one virus-binding peptide and/or virus-binding small molecule immobilized onto the surface of the nano- or microparticle. These nano- or microparticle forms aggregates with targeted viral particles to initiate phagocytosis, thereby achieving viral clearance. The present invention further relates to uses of the functionalized nano- or microparticles in virus detection, therapy and diagnosis.
Resumen de: AU2023307461A1
The present invention relates to a high-Z element containing nanoparticles for use in a method of treating a tumor by radiopharmaceutical therapy, in a subject in need thereof, the method comprising a combined administration of an efficient amount of said high-Z element containing nanoparticles and of an efficient amount of a radionuclide containing therapeutic radiopharmaceutical, wherein the high-Z element containing nanoparticles contain an element with an atomic Z number higher than 40, preferably higher than 50, and wherein said nanoparticles have a mean hydrodynamic diameter of 20 nm or less, for example between 1 and 10 nm, preferably between 2 and 8 nm.
Resumen de: EP4555999A1
The present invention provides lipid nanoparticles containing(A) an ionic lipid represented by the formula (1):(the symbols in the formula (1) are as defined in the DESCRIPTION),(B) vitamin E and/or a derivative thereof,(C) phospholipid,(D) cholesterol, and(E) PEG lipid.
Resumen de: CN120019820A
本发明涉及一种脂质纳米颗粒，其包含：可电离脂质、磷脂、聚乙二醇‑脂质、固醇；其中，所述固醇具有下式(I)的结构#imgabs0#其中，R1、R2、R3、A环、B环、C环、D环和T具有说明书的定义；脂质纳米颗粒的硬度为28～105MPa。本发明还涉及脂质纳米颗粒的制备方法及其在制备用于预防或治疗传染病、脂肪肝、肿瘤以及自身免疫病的药物组合物用途。
Resumen de: US2025051502A1
A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.
Resumen de: CA3213930A1
A population of capsules, the capsules can include a core including a benefit agent and a shell surrounding the core, wherein the shell can include a first shell component.
Resumen de: CN120005104A
本发明涉及一种pH响应型聚氨酯纳米材料、药物递送系统及制备方法，包括以下步骤：S1，以异氰酸酯与联萘酚为原料，在含有催化剂的有机溶剂中合成联萘基聚氨酯，再加入封端剂，经封端反应得到封端联萘基聚氨酯；S2，向封端联萘基聚氨酯中加入苯硼酸和引发剂，通过自由基聚合法，得到苯硼酸联萘基聚氨酯聚合物；S3，苯硼酸联萘基聚氨酯聚合物与单宁酸反应，制得pH响应型聚氨酯纳米材料。本发明pH响应型聚氨酯纳米材料的疏水核心为末端接枝苯硼酸的聚氨酯，亲水端为多酚羟基的单宁酸，增加了pH的响应性，且能够有效增加药物负载率，具有良好的生物相容性和抗肿瘤效果，同时，具有一定的抗氧化和抗菌能力。
Resumen de: CN120005884A
本发明提供本发明涉及生物医学技术领域，特别是涉及一种干扰Tcl1a基因表达的siRNA、核壳型纳米粒子及其制备方法和应用。该方法涉及一种在NOD模型鼠上，使用靶向小鼠Tcl1a基因的核壳型纳米粒子(siTcl1a NPs)治疗I型糖尿病的内容，并提供该纳米粒子的制备方法。将干扰Tcl1a基因的siRNA与阳离子脂质体G0‑C14混合，得到络合物；将络合物与聚乳酸‑羟基乙酸共聚物混合，得到核物质；将核物质与脂质聚合物混合，得到核壳型纳米粒子。本发明提出可以通过靶向Tcl1a基因调控来治疗I型糖尿病的治疗策略。
Resumen de: CN120004829A
本发明公开了一种NIR‑II发射的J聚集诱导发光光敏剂及其构建的药物组合物、制备方法和应用。该光敏剂在光照下可产生细胞毒性I型活性氧，具有优异的NIR‑II区荧光成像能力以及光疗性能。该光敏剂进一步与索拉非尼共组装成药物组合物，具有J聚集诱导的二次自组装特性，实现了在肿瘤部位长时间成像，发挥NIR‑II区荧光成像与肿瘤治疗的双重功能，稳定性好，毒副作用低，临床应用前景广泛。#imgabs0#
Resumen de: CN120000806A
本发明提出了一种基于介孔二氧化硅的肿瘤靶向纳米材料及其制备方法，所述制备方法，包括以下步骤：将介孔二氧化硅球的表面胺基化，得到MCM‑41‑NH2；在MCM‑41‑NH2上负载钆，得到MCM‑41‑NH2@Gd；在MCM‑41‑NH2@Gd上组装DOX，得到MCM‑41‑NH2@Gd@DOX；在MCM‑41‑NH2@Gd@DOX上修饰官能团FA+APTES、3(EtO)Si‑Se‑Se‑Si(EtO)3、NH2‑PEG+O＝N＝C‑Si(OEt)3，得到MCM‑41‑NH2@Gd@Se‑Se@DOX@FA。本发明的介孔二氧化硅球具有长程有序的二维六方介孔结构，DOX等装载到了介孔二氧化硅球的孔道内。
Resumen de: CN120000616A
本发明公开了一种PEG包覆的铕基MOFs纳米复合材料及其制备方法和应用，该纳米复合材料包括核结构和壳结构；所述核结构包括铕基有机骨架（Eu‑MOF），以及负载于铕基有机骨架上的银纳米颗粒(AgNPs)和紫杉醇(PTX)；所述壳结构为聚乙二醇（PEG），包裹在所述核结构外部。本发明利用金属配位、物理吸附和π‑π作用将Eu‑MOF、光热剂银纳米粒(AgNPs)及PTX共组装，并使用PEG包裹增强其分散性，构建了一种用于肿瘤微环境pH响应的多功能纳米复合物。该纳米复合物展现了出色的荧光成像和光热成像能力，能够提供清晰的肿瘤定位和监测，通过光热治疗和化疗的双模联合治疗显著提升了乳腺癌的治疗效果。
Resumen de: CN120000617A
本发明涉及生物医用领域，具体提供一种聚合物载药纳米颗粒及其制备方法、用途，旨在通过特异性识别及自噬激活途径有效清除巨噬细胞内的Fn。为此目的，本发明的聚合物载药纳米颗粒的制备方法包括：通过D‑甘露糖胺盐酸盐和甲基丙烯酰氯的反应制备第一单体；通过二茂铁甲醇和甲基丙烯酰氯的反应制备第二单体；将所述第一单体和第二单体聚合成两亲性的嵌段共聚物；将所述嵌段共聚物与青蒿琥酯共混，自组装得到聚合物载药纳米颗粒。本发明提供的聚合物载药纳米颗粒制备过程简便、成本低廉，且具有良好的生物相容性，其能够高效清除巨噬细胞内的Fn，具有广泛的应用前景，可广泛应用于材料学、生物学和医学等领域。
Resumen de: CN120004914A
本发明公开了一种兼具光热和光动力效应的共轭小分子光敏剂及其制备方法与应用，PS‑表面活性剂复合纳米粒子的方法包括以下步骤：将共轭小分子光敏剂溶于第一溶剂中，得到光敏剂溶液，将表面活性剂溶于第二溶剂中，得到表面活性剂溶液，将光敏剂溶液和表面活性剂溶液混合均匀，得到混合液，在超声条件下，将混合液滴加至第三溶剂中并搅拌，得到光敏剂‑表面活性剂溶液，将光敏剂‑表面活性剂溶液置于第四溶剂中透析，冷冻干燥，得到PS‑表面活性剂复合纳米粒子，该PS‑表面活性剂复合纳米粒子兼具PTT和PDT活性，其抗菌活性高，具有广谱抗菌能力，且生物相容性好。
Resumen de: CN120000587A
本发明涉及一种具有可变形性的抗原递送载体及其制备方法和应用，所述具有可变形性的抗原递送载体具有水包油包水型乳液结构，其中内水相为含有正电性纳米颗粒的悬浊液，油相为含有亲油性乳化剂的油性物质，外水相为含有亲水性乳化剂的溶液。本发明提供的抗原递送载体具有可变形性，在与细胞接触时可以通过变形增大接触面积，同时内水相中的正电性颗粒可高效吸附或包埋抗原，提高其生物利用度，并利用颗粒的正电性强化“质子泵效应”，促进溶酶体破裂释放抗原，使细胞免疫应答效果大幅提升，进而实现体液及细胞双重免疫应答的增强。
Resumen de: CN120004831A
本发明公开一种分子探针及其制备方法与应用，涉及荧光探针技术领域。所述分子探针的结构式为：#imgabs0#本发明以共价连接的两个相同花菁单元作为母体，并同时在两个花菁单元中引入还原型谷胱甘肽响应基团，构建成一种可清除还原型谷胱甘肽的同时，实现NIR‑II荧光信号开启的分子探针即双花菁分子探针。该分子探针可通过消耗肿瘤细胞内的还原型谷胱甘肽诱发细胞铁死亡。此外，该分子探针本身具有很高的光热转换效率，可对肿瘤细胞进行光热治疗。因此，本发明提供的分子探针是集NIR‑II荧光响应、铁死亡诱导和光热治疗于一体的伴随诊断试剂，具有优异的抗肿瘤效果，应用前景广阔。
Resumen de: CN120000614A
本发明公开了一种含冷冻保护剂的复合型脂质纳米颗粒及其制备方法和应用。本发明的复合型脂质纳米颗粒包括脂质纳米粒(LNP)和冷冻保护剂；所述脂质纳米粒包括载体、被包封的核酸；所述载体包括可离子化脂质、辅助磷脂、胆固醇类物质和聚乙二醇化脂质；所述冷冻保护剂至少包括甜菜碱。本发明制备的复合型脂质纳米颗粒中的冷冻保护剂可以在冷冻复温处理中保护LNP不被破坏，起到良好的冷冻保护作用。同时在冷冻复温处理后，所述冷冻保护剂还可以整合到LNP中，可以提高LNP的膜融合效率。本发明通过提高LNP的内体逃逸效率，进而提高LNP的体内和体外转染效率。
Resumen de: CN120000758A
本发明属于中药艾灸组合物技术领域，具体涉及一种温经散寒草本艾灸条及其制备方法。所述艾灸条的组成包括下述组分：艾叶、桂枝提取物、透骨香、路路通、丝瓜络、川芎提取物、白芷提取物、丁香提取物、蜂蜜、干姜、苍术提取物、薄荷脑、糯米浆、电气石粉、黄原胶、聚乳酸‑羟基乙酸共聚物和竹纤维。本发明通过艾绒与电气石协同产热，结合聚乳酸‑羟基乙酸共聚物微球缓释川芎、桂枝提取物，实现药物分层释放，竹纤维调控燃烧稳定性，丝瓜络‑蜂蜜载体吸附药物，苍术、白芷快速起效，酶解工艺增强艾叶、干姜活性，远红外促进透皮吸收，形成温经散寒的长效治疗体系。
Resumen de: CN120000615A
本发明公开了一种细菌代谢酶响应型配位聚合物载体的构建及应用。本发明将抗菌增敏剂紫草素与金属离子配位形成骨架内核，随后将细菌代谢酶响应断键的前药分子载于由磷脂和两亲性嵌段共聚物组成的外层磷脂双分子层中，构建了一种同步递送前药分子和金属离子的配位聚合物递药系统。该递药系统具有良好的酸稳定性和黏液渗透性，在到达胃幽门螺杆菌感染部位后，其中的前药分子可响应细菌染微环境的代谢酶而断键，争夺配位骨架内核中的金属离子，形成具有细菌杀伤作用的络合物并释放紫草素，实现对幽门螺杆菌特异性杀伤的同时避免了对哺乳动物细胞产生毒性，为幽门螺杆菌感染的治疗提供了一条新的途径。
Resumen de: CN120000787A
本发明提供了胸腺五肽、盐霉素与IR780碘化物联合使用在制备治疗抑制肿瘤干性的药物中的用途。本发明还提供了一种抑制肿瘤干性的药物组合物。本发明是以盐霉素为基础的内质网应激纳米诱导剂（DTSS），以协同抑制癌细胞干性，有效增敏癌症免疫治疗。内质网靶向的光疗药物s‑780通过偶联对甲苯磺酰胺和IR780碘化物（IR780）制备，并与胸腺五肽和盐霉素共同组装，最后用生物素功能化，获得特定位点的递送纳米平台（DTSS），能有效激活系统性抗肿瘤免疫反应，抑制癌症的转移和复发，为通过抑制癌细胞干性增敏癌症免疫治疗提供了有希望的解决方案。
Resumen de: WO2025101580A1
Linker chemistry has been developed that provides a means to couple antibody fragments in an oriented fashion, using covalent bonding to form polymer-antibody fragment conjugates. The antibody fragments can be included to polymeric nanoparticles by covalent bonding to a polyalkylene oxide segment of either a poly(amine-co-ester) polymer or a polyester a thio-ether bond. Because conjugation of the antibody to the polymer occurs via specific residues of the antibody, the orientation of the antibody on the surface of the polymeric particles can be precisely controlled to enhance interactions with proteins, cells, and tissues. Also described are methods of using the conjugates.
Resumen de: AU2023366039A1
The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus.
Resumen de: WO2025098967A1
The present invention provides a complex for use in delivering a cargo across a mucus barrier, the complex comprising a particle with a surface coated with catalase; and the cargo, wherein the catalase is attached over the whole surface of the particle. The invention also provides a pharmaceutical composition comprising the complex, and the complex or the pharmaceutical composition for use in a therapeutic, prophylactic, and/or diagnostic method.
Resumen de: JP2024153644A
To provide a method for treating cancer.SOLUTION: The method comprises selectively selecting and administering a nanoparticle that brings about transient expression of an anti-ROR1 CAR, an anti-CD19 CAR or a hepatitis B antigen-specific TCR by T cells following administration to a subject; monitoring the subject for expression of the anti-ROR1 CAR, anti-CD19 CAR or hepatitis B antigen specific TCR, and administering a second therapeutically effective amount of the selected nanoparticle to the subject when the expression level falls below a threshold, where the selected nanoparticle comprises: (i) an in vitro transcribed (IVT) mRNA encoding the anti-ROR1 CAR, anti-CD19 CAR or hepatitis B antigen specific TCR encapsulated within a poly(β-amino ester)(PBAE) core; (ii) a polyglutamic acid (PGA) coating on the outer surface of the PBAE core; and (iii) a CD4 and/or CD8 binding domain covalently linked to the PGA and extending from the coating surface.SELECTED DRAWING: None
Resumen de: MX2020011339A
Provided is a polymer comprising a structure of Formula (1): (1) and a method of preparing said polymer. Also provided is a composition comprising the polymer and a nucleic acid and/or polypeptide, and a method of delivering a nucleic acid and/or polypeptide to a cell.
Resumen de: US2025144037A1
Provided are a mRNA vaccine composition with improved storage stability and a method of improving storage stability of the vaccine composition.
Resumen de: WO2025100777A1
The present application relates to surface-modified nanoparticles and drug delivery uses thereof.
Resumen de: KR20250067750A
본 발명은 생강과 식물인 자바강황(Curcuma xanthorrhiza)의 에탄올 추출물(CXE)을 함유한 나노구조 지질 운반체(NLCs)에 관한 것으로서, 잔토리졸(xanthorrhizol)과 커큐민(curcumin)을 함유한 자바강황(Curcuma xanthorrhiza)을 에탄올로 추출하여 NLC에 탑재하여 생체이용률과 생리 활성이 향상된 기능성 식품(nutraceuticals) 및 의약품용 조성물에 관한 발명이다.
Resumen de: AU2023262597A1
Peptide-based colloidal particles that are able to encapsulate and stabilize non-polar excipients, including room temperature solid lipids, and hydrophobic and/or poorly water-soluble active agents for storage and delivery in aqueous mediums, methods of making and using the same. Methods of customizing and resizing such colloids. Peptide-based colloidal particles as delivery vehicles for various hydrophobic and/or poorly water-soluble active agents.
Resumen de: MX2024012090A
The present application is directed, in general, to tolerizing immune mediated particles comprising gene therapy vector antigens for use in combination with gene therapy regimens in order to reduce immunogenicity to the gene therapy vector antigens and/or transgene protein products expressed by the vectors.
Resumen de: AU2023379457A1
The present invention provides, in part, protein-drug conjugates comprising an anti-fibroblast growth factor receptor 3 (FGFR3) (e.g., human FGFR3) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, polypeptides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain). Methods for treating various diseases or disorders, such as neurological diseases, with the conjugates are provided.
Resumen de: AU2023402610A1
This disclosure provides a bispecific canine antigen-binding molecule comprising a first antigen binding domain or antigen-binding portion thereof that specifically binds canine CD3, and a second antigen binding domain or antigen-binding portion thereof that specifically binds canine CD20, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD3, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD20, compositions comprising the same, and methods of their use.
Resumen de: WO2025097659A1
Related generally to lipids, lipid nanoparticle formulations, and methods of using the same for delivering nucleic acids, such as mRNA.
Resumen de: WO2025101911A1
Disclosed herein are compositions comprising LNPs capable of selectively targeting cancer cells in organs for the efficient delivery of RNA cargos, specifically aimed at targeting poorly druggable, disease-driving transcription factors in prostate cancer and methods of use thereof.
Resumen de: WO2025101704A1
The disclosure relates to compositions and methods for improving pulmonary delivery of therapeutic nucleic acids, e.g., DNA, mRNA, by enhancing transfection efficiency and thus efficacy of the therapeutic nucleic acids, using inhaled, Intranasal, Intratracheal, bronchial instillation and/or topical administration Intratracheal, bronchial instillation and/or topical administration transfection efficiency enhancing agents, including but not limited to 2-mercaptoethane sulfonate or cysteamine.
Resumen de: WO2025101966A1
The present disclosure provides compositions and methods for enhancing transplant tolerance comprising therapeutic agents that increase HIF-2α expression and/or activity. The therapeutic agents are loaded onto PEG-bl-PPS nanocarriers for targeted delivery to myeloid cells.
Resumen de: WO2025101030A1
The present invention relates to a nanostructure and use thereof, the nanostructure comprising: a polymer material having a cyclodextrin-derived functional group chemically bonded thereto; and a guest material where a first moiety with a molecular diameter larger than 4.7 Å and a second moiety with a molecular diameter smaller than 4.7 Å are bonded to each other.
Resumen de: WO2025100747A1
The present invention relates to novel ecto-liposome nanoparticles. More specifically, the present invention provides novel ecto-liposome nanoparticles exhibiting tumor site targeting ability superior to that of a conventional drug carrier having targeting ability, and thus can be used as a drug carrier that loads a drug such as an anticancer drug so as to release the drug systemically or locally, and can be used as a therapeutic agent for treating refractory cancer or metastatic tumor.
Resumen de: WO2025100737A1
The present invention relates to a novel ionizable lipid and a lipid nanoparticle composition comprising same. Lipid nanoparticles formed from a novel ionizable lipid compound, according to the present invention, exhibit an excellent gene encapsulation rate and in vivo gene delivery rate, and moreover, exhibit an excellent gene delivery function even in a liver damage model, and thus may be usefully employed as a composition for drug delivery.
Resumen de: WO2025100777A1
The present application relates to surface-modified nanoparticles and drug delivery uses thereof.
Resumen de: WO2025100466A1
This complex for use in tumor chemodynamic therapy comprises: nanoparticles that enclose iron oxide and include a hydrophilic polymer in a surface layer thereof; and target recognition molecules that bind to the nanoparticles and can bind to target molecules of the tumor cells.
Resumen de: WO2025100652A1
The present specification discloses an intraocular drug delivery system using magnetic nanoparticles. In an aspect, unlike existing drug delivery systems, the drug delivery system of the present invention can adjust and control, from outside the eyeball, drug movement and a drug release position after intraocular drug injection, and can replace repeated expensive injection treatments, and thus can reduce burden on patients, medical personnel, and national healthcare finances.
Resumen de: WO2025101020A1
The present invention relates to: quetiapine-fatty acid conjugate nanoparticles using fattigation technology; and use thereof as a long-acting injection. More specifically, the present invention provides self-assembled nanoparticles and a long-acting injectable composition comprising same, the self-assembled nanoparticles comprising a quetiapine-fatty acid conjugate in which one or more fatty acids are conjugated to quetiapine or a pharmaceutically acceptable salt thereof, and being formed by self-assembly according to pH changes. When the composition according to the present invention is administered into the body, the bioavailability, half-life, and the like of quetiapine are improved and the composition exhibits excellent long-acting release characteristics, and thus medication compliance of patients with mental disorders can be improved by using the composition.
Resumen de: WO2025100828A1
The present invention relates to a novel ionizable lipid and a lipid nanoparticle composition using same. Lipid nanoparticles formed using the novel ionizable lipid exhibit an excellent gene encapsulation rate and intracellular/in vivo gene delivery rate, and exhibit excellent muscle delivery of genes through local injection, and thus can be effectively used as a composition for drug delivery.
Resumen de: WO2025100731A1
The present invention relates to nanoparticles capable of charge conversion and medical use thereof. More specifically, provided are: nanoparticles formed by self-assembling a compound in which a photosensitizer is encapsulated in a cyclodextrin derivative conjugated with a zwitterionic near-infrared fluorophore; and a photodynamic or photodynamic/chemotherapeutic composition thereof for diagnosing or treating cancer, thereby enhancing anticancer efficacy through synergistic effects thereof.
Resumen de: WO2025098237A1
A lyophilized RNA-LNP (e.g., mRNA-lipid nanoparticle), a method of making or using the same, such as for vaccination using an mRNA encoding an antigenic vaccine (e.g., SARS-CoV-2).
Resumen de: WO2025097544A1
Provided are a transdermal delivery system for nanodrug, a preparation method therefor, and use thereof. In the described transdermal delivery system for nanodrug, lipoic acid is used as a drug carrier to encapsulate a chemotherapeutic drug and/or a photodynamic agent, and nanoparticles containing 1,2-dithiolane are formed by means of self-assembly. For the first time, lipoic acid is used as a carrier-assisted small molecule in the transdermal delivery system, which eliminates the need for an additional transdermal penetration enhancer. The system is not restricted by the location of the skin or the number of appendages, and does not require the assistance of devices for drug administration, but only simple application to achieve efficient transdermal penetration. The drug administration method is non-invasive, allowing for efficient transdermal penetration without disrupting the stratum corneum, thereby reducing the risk of skin infection. The depth of transdermal penetration can reach 1 mm or more, making the system suitable for both superficial and deep skin diseases. The system can be operated independently, significantly reducing costs and providing high safety. On the basis of this, the type of drug to be loaded can be flexibly changed according to the type of skin disease, enabling more precise treatment.
Resumen de: WO2025097534A1
Provided are an oligonucleotide conjugate, an exosome conjugate comprising the same, and application thereof. The oligonucleotide conjugate comprises: R1-L-R2, or an isomer and a pharmaceutically acceptable salt thereof; wherein R1 is a targeting group; R2 is an oligonucleotide; L is a linker. Also provided is an exosome conjugate comprising the oligonucleotide conjugate. Compared with the prior art, the exosome conjugate remarkably improves the siRNA loading capacity, the loading efficiency, and the loading stability of the exosome. The treatment effect is superior to that of a conjugate prepared by an existing TEG linker in the aspect of long-acting performance. The exosome conjugate has a wide application prospect in clinical medical treatment.
Resumen de: WO2025098101A1
The invention relates to a compound, a lipid compound nanoparticle, a nucleic acid nanoparticle complex, a pharmaceutical composition and uses thereof in the drug delivery field, and belongs to the fields of biomedicine and biotechnology. The structure of the compound is shown as formula A. The compound, lipid compound nanoparticle or nucleic acid nanoparticle complex provided herein has the advantages of good biocompatibility, high transfection efficiency, low toxicity and excellent technical effects.
Resumen de: US2025152735A1
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
Resumen de: US2025152699A1
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
Resumen de: US2025154102A1
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
Resumen de: US2025152736A1
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Compositions optionally comprising a nanoparticle carrier and nucleic acid sequence(s) encoding for (i) a cytokine; and (ii) an innate immune stimulator are provided. Further provided are compositions optionally comprising a nanoparticle carrier; an innate immune stimulator; and a nucleic acid sequence encoding for a cytokine. Methods of using the compositions as a therapeutic vaccine for the treatment of a cancer are also provided.
Resumen de: US2025152734A1
Disclosed herein are compositions, formulations, and methods that include nanoparticles comprising camptothecin-conjugated mucic acid polymers.
Resumen de: US2025152733A1
“Two-faced” amphiphilic Janus nanoparticles that have different surface chemistries on two hemispheres. One hemisphere of the Janus nanoparticles is functionalized with a hydrophobic moiety. The other hemisphere of the nanoparticles is functionalized with either a cationic antibiotic or cationic polymer. Janus nanoparticles effectively inhibit the growth of both Gram-negative and Gram-positive bacteria at picomolar concentrations and may be used as a broad-spectrum antibiotic on surfaces or to treat bacterial infections in patients.
Resumen de: US2025152732A1
The present invention relates to an antibody-bound lipid nanoparticle comprising an antibody conjugated with a membrane scaffold protein, and more specifically relates to an antibody-bound lipid nanoparticle which comprises a lipid, and an antibody conjugated with a membrane scaffold protein, and which can be easily produced and has an excellent specific targeting ability.
Resumen de: US2025152756A1
The present invention relates, inter alia, to a method for functionalizing a cyanoacrylate-based material comprising the steps of providing a cyanoacrylate-based material having ester groups; providing a ligand having an amino group; contacting the cyanoacrylate-based material with the ligand under conditions favoring aminolysis of the amino group of the ligand and the ester groups of the cyanoacrylate-based material; and optionally obtaining the cyanoacrylate-based material functionalized with the ligand.
Resumen de: US2025152744A1
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a disorder-related polypeptide. Also provided are methods to treat various neurodegenerative disorders. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions and kits for expressing a disorder-related polypeptide in an individual in need thereof.
Resumen de: US2025152737A1
The present disclosure relates to lipid nanoparticles (LNPs) comprising VEE replicon, wherein the LNPs are useful for selectively reducing and/or avoiding the expression of a payload within the liver. The present disclosure also relates to the use of such LNPs to treat various diseases and disorders.
Resumen de: US2025152681A1
The present invention relates to a nanodisc comprising angiotensin converting enzyme 2 (ACE2) and a membrane scaffold protein (MSP). In the present invention, the angiotensin converting enzyme 2 (ACE2) is included in the nanodisc, and it was confirmed that the antiviral efficacy and substrate conversion ability of the angiotensin converting enzyme 2 (ACE2) could be significantly improved.
Resumen de: US2025152655A1
Provided are methods for modulating gut microbiota in subjects. In some embodiments, the methods include administering to a subject an effective amount of a composition that includes a first edible plant-derived nanoparticle encapsulating an effective amount of RNA. Also provided are methods for preventing and/or treating gut dysbiosis, methods for modulating bacterial growth, methods for modulating inflammatory cytokines, methods for reducing migration of bacterial from the gut to gut-associated bloodstream, and compositions for use in the presently disclosed methods, including pharmaceutical compositions.
Resumen de: US2025152657A1
Provided is a composition for promoting hair growth, which comprises a mixture comprising an extract of Polygonum multiflorum Thunb and silver nanoparticles; and Copper Tripeptide-1, wherein the weight/volume ratio of the Copper Tripeptide-1 to the composition for promoting hair growth is from 0.1 mg/mL to 0.2 mg/mL; wherein the mixture comprising the extract of Polygonum multiflorum Thunb and silver nanoparticles comprises the silver nanoparticles, extract of Polygonum multiflorum Thunb, a stabilizer, and a diluent. The present invention further provides a pharmaceutical composition for promoting hair growth comprising the composition and a pharmaceutically acceptable excipient, and a method for promoting hair growth by administering the pharmaceutical composition to a subject. The composition for promoting hair growth of the present invention can increase hair growth and stimulate the growth of new hair follicles.
Resumen de: US2025152739A1
The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.
Resumen de: US2025152622A1
An aluminum-manganese composite nanocrystal, and a preparation method therefor and the use thereof. The method for preparing the aluminum-manganese composite nanocrystal comprises: step 1, mixing an aluminum salt solution, a manganese salt solution and an anionic adjuvant solution to obtain a mixture, and adjusting the pH value of the mixture to 5.5-8.5; and step 2, heating the mixture for a reaction, and washing the obtained solid reactant to obtain the aluminum-manganese composite nanocrystal. According to the aluminum-manganese composite nanocrystal prepared using the preparation method and the use thereof in the preparation of a vaccine adjuvant, a pharmaceutical composition, a drug delivery carrier or an immunogenic composition, the technical problem that an existing aluminum adjuvant cannot activate humoral immunity and cell immunity at the same time can be effectively solved.
Resumen de: US2025154486A1
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV). The present invention also encompasses methods of using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of a HBV infection, or treating hepatocellular carcinoma (HCC). Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or HCC.
Resumen de: US2025154317A1
Methods to produce branching poly(amine-co-ester) (bPACE) polymers having more than two end groups per single polymer, where the amine content can be controlled by end-group modification, have been developed. The resulting bPACE polymers are particularly well suited for delivery of nucleic acid molecules, showing strong complexation, stability, better transfection and expanded routes of administration. Advantages of bPACE include polyplexes with branched polymer present positive charges, even with large amount of nucleic acid (strong and rigid complexation to limited number of nucleic acid), even in neutral pH (7.4, PBS). Transfection by bPACE performs better than linear PACE at a lower weight ratio, showing high expression in vivo. Advantages of bPACE also include polyplexes with branched polymer present better stability in neutral pH, physiological condition, maintaining transfection abilities.
Resumen de: US2025154225A1
Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, disorder, or condition, including cancer, are disclosed.
Resumen de: US2025152725A1
This disclosure relates to therapies in which an antibody drug conjugate is administered together with a composition comprising nanoscale cavitation initiators. Application of ultrasound following administration provides effective, targeted delivery of antibody drug conjugate to the diseased site. The therapies are useful in the treatment of solid tumour.
Resumen de: US2025152561A1
Disclosed are compositions and methods that provide synthetic nanocarriers that comprise hydrophobic polyester carrier material and rapamycin that is in a stable, super-saturated amount. In some embodiments, the synthetic nanocarriers are also initially sterile filterable. In other embodiments, the rapamycin is present in the synthetic nanocarrier compositions in an amount that is less than 50 weight % rapamycin/hydrophobic polyester carrier material in the composition.
Resumen de: US2025152623A1
Many next-generation biomaterials will need the ability to not only promote healthy tissue integration but to simultaneously resist bacterial colonization and resulting biomaterials-associated infection. For this purpose, antimicrobial nanofibers of polycaprolactone (PCL) were fabricated by incorporating calcium peroxide. PCL nanofibers containing different ratios of calcium peroxide (1%, 5% and 10% (w/w)) with or without ascorbic acid were fabricated using an electrospinning technique. Antimicrobial evaluations confirmed the inhibitory properties of the nanofibers on the growth of E. coli and S. epidemidis because of a significant burst release of calcium peroxide from the nanofibers. Analysis of tissue cell response showed that despite an initial toxic effect over the first 24 h, after 4 days of culture, osteoblast viability and morphology were both healthy. These results demonstrate that oxygen-generating nanofibers can be designed and developed to provide a short-term peroxide-based antimicrobial response while still maintaining attractive tissue-integration properties.
Resumen de: US2025152563A1
The present invention provides methods and compositions for treating a hyperplasia (such as cancer, restenosis, or pulmonary hypertension) by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and an albumin based upon the status of an mTOR-activating aberration.
Resumen de: US2025152501A1
The present disclosure relates to a dissolving microneedle for transdermal delivery of biopharmaceuticals and a method of manufacturing the same. In the dissolving microneedle of the present disclosure, since biopharmaceuticals form a nanocomposite with aminoclay, the stability of the biopharmaceuticals and the mechanical strength of the microneedle are high, and the skin permeability of the biopharmaceutical is increased, thereby greatly improving transdermal delivery efficiency.
Resumen de: US2025152518A1
The present disclosure in part provides compounds (i.e., PEG lipids) which are useful in pharmaceutical compositions, cosmetic compositions, and drug delivery systems, e.g. for use in lipid nanoparticle (LNP) formulations. The present disclosure also provides LNP formulations comprising PEG lipids described herein, and methods of using the same. For example, the LNPs provided herein are useful for the delivery of an agent (e.g., therapeutic agent) to a subject. The PEG lipids and LNPs provided herein, in certain embodiments, exhibit increased PEG shedding compared to existing PEG lipids and LNP formulations.
Resumen de: US2025152509A1
Particles, aqueous dispersions, and liquid compositions having high lipophilic component concentrations and high lipophilic component to surfactant ratios are described. The particles, aqueous dispersions, and liquid compositions can be used to efficiently deliver active compounds and/or active ingredients, such as cannabinoids including cannabidiol (CBD), through a variety of formulation types.
Resumen de: US2025152512A1
A nitrogen-branched non-linear PEGylated lipid containing a tertiary amine, which is represented by the Formula (1); wherein, B1 and B2 are linking bonds or alkylene groups; L1, L2, Ld and Lx are linking bonds or divalent linking groups L; R1 and R2 are C1-50 aliphatic hydrocarbon groups or C1-50 residues of aliphatic hydrocarbon derivative, each containing 0-10 heteroatoms; Ncore is a multivalent group of valence y+1 and contains a trivalent nitrogen-atom branching core connected to Ld; y is 2, 3, 4, 5, 6, 7, 8, 9, or ≥10; XPEG are polyethylene glycol components. Compared with linear PEGylated lipids, the nitrogen-branched PEGylated lipid herein can realize better surface modification of LNP. The present invention also provides a lipid pharmaceutical composition and its formulation containing the PEGylated lipid, which can enhance the targeting ability of drugs and improve the transfection efficiency of nucleic acid drugs.
Resumen de: US2025152515A1
Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.
Resumen de: US2025152587A1
A compound of formula Ior a pharmaceutically acceptable salt or ester thereof is provided for the treatment of cancer wherein(i) the cancer is one that has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy and(ii) the treatment is with a dose of between 1 mg/m2 and 30 mg/m2 of compound per patient body surface area per administration.Method of treatment and novel dosage forms are also provided.Particularly treated are ovarian cancers, particularly those expressing α-folate receptors, including epithelial ovarian, fallopian tube or peritoneal cancer.
Resumen de: AU2023387066A1
It provides a method for treating and/or preventing edematous fibrosclerotic panniculopathy (EFP) in a subject in need thereof. The method includes administering to the subject an effective amount of a pharmaceutical composition. The pharmaceutical composition includes a plurality of amphiphilic nanoparticles having one or more active ingredients encapsulated therein. Each of the amphiphilic nanoparticles is formed by a non-ionic surfactant, a polymeric carrier, or a lipid carrier. The hydrophilic-lipophilic balance (HLB) value of the non-ionic surfactant is greater than 9. The pharmaceutical composition is administered via a parenteral route by an injection, a microneedle, or an implant, or via topical administration or transdermal administration.
Resumen de: AU2023373016A1
Provided is an oral-administration-type vaccine composition containing an antigen and fibroin-containing nanoparticles.
Nº publicación: WO2025098544A2 15/05/2025
Solicitante:
CENTRO DE INVESTIG Y DESARROLLO DE MEDICAMENTOS CIDEM [CU]
CENTRO DE INVESTIGACI\u00D3N Y DESARROLLO DE MEDICAMENTOS. CIDEM
Resumen de: WO2025098544A2
The present invention describes the procedure for obtaining nanocrystals of isolated xanthatin from a natural source. It further describes pharmaceutical compositions comprising such nanocrystals, as well as the uses and methods of treatment in which they may be used.
BOPI
Sede Electrónica
